DossierENTITY

heart drug developer

Coverage of heart drug developer in the Nexus archive.

Earliest in view: Jun 11 · 13:40 UTCMost recent: Jun 11 · 13:40 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 11 · 13:40 UTCQUARTZ
Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. IPO
Kardigan, a heart drug developer, is targeting a $1.4 billion valuation through its U.S. IPO. The company plans to raise up to $373.3 million by selling 23.3 million shares priced between $14 and $16 each.